A Phase 1/2, Open-Label, Adaptive, Randomized Study of Liposomal Doxorubicin With or Without M200 (Volociximab) for the Treatment of Subjects With Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer That Have Relapsed After Prior Therapy With a Platinum/Taxane-Based Chemotherapy

Inclusion Criteria:

- Females aged >= 18 years old at the time of informed consent.

- Advanced (Stage III or IV) histologically documented epithelial ovarian cancer or
primary peritoneal cancer (excluding small, round-cell histologies).

- Recurrent or persistent disease.

- Received no more than 2 prior cancer treatment regimens, at least one of which must
have included a platinum/taxane based therapy. If the same regimen is given more than
once, it will count as one regimen. If components of a regimen are given more than
once using the same schedule, it will count as one regimen.

- At least 1 target lesion to assess response by RECIST criteria. (Tumors within a
previously irradiated field are designated as non-target)

- Other protocol-defined inclusion criteria apply.

Exclusion Criteria:

- Subjects taking immunomodulatory agents including, but not limited to, interferons,
interleukins, systemic steroids, cyclosporine, tacrolimus, calcineurin inhibitors,
chronic low dose methotrexate, or azathioprine. (Use of inhaled or intranasal
steroids or oral steroids 10 mg/day prednisone or its equivalent are permitted.)

- Subjects who require treatment with an anti coagulant with the exception of low dose
Aspirin® (81 mg/day), warfarin (1 mg/day), or heparin for IV catheter patency

- Evidence of bleeding diathesis or coagulopathy. (Prior history of DVT will not
exclude subjects from participating in this study.)

- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal
abscess within 6 months prior to Day 1.

- Non-healing wound, ulcer, or bone fracture.

- Evidence of autoimmune disease including, but not limited to, ulcerative colitis,
Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, and
other disease in which immune function or immune competence is known to be impaired.

- Active infection requiring systemic antibiotics, antivirals, or antifungals including
HIV/AIDS, hepatitis B, or hepatitis C infection.

- Other protocol-defined exclusion criteria apply